Clinical Trial Update: Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation [Phase 2]

View source ↗

Summary

Open-label Phase II trial evaluating isatuximab for patients with refractory immune cytopenias after allogeneic hematopoietic cell transplantation is ongoing bu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blood Cancer
• Immune Cytopenia

Drugs mentioned

• SARCLISA (isatuximab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Blood Cancer, Refractory Immune Cytopenias | Phase 2 | Status: ACTIVE_NOT_RECRUITING